Byline: Jeneen Interlandi
A vaccine that would teach the immune system to attack and destroy cocaine before the drug reached the brain is poised to enter its first large-scale clinical trial in humans. The shot is still years away from FDA approval, but the underlying concept -- inoculating those at risk of addiction -- is attracting increased interest.
Besides cocaine, researchers are developing vaccines against such highly addictive substances as nicotine, heroin and methamphetamine. NicVax, a nicotine vaccine by Nabi Biopharmaceuticals, is the furthest along in development. In November, one year into a phase-two clinical trial, the company reported that twice as ...